Sanara MedTech
SMTI
20 hedge funds and large institutions have $17.2M invested in Sanara MedTech in 2021 Q1 according to their latest regulatory filings, with 11 funds opening new positions, 5 increasing their positions, 2 reducing their positions, and 6 closing their positions.
231% more capital invested
Capital invested by funds: $5.2M → $17.2M (+$12M)
150% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 2
83% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 6
33% more funds holding
Funds holding: 15 → 20 (+5)
5.85% more ownership
Funds ownership: 1.66% → 7.51% (+5.8%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$7.8M |
| 2 |
MS
Maven Securities
St Helier,
Jersey
|
+$2.43M |
| 3 |
LCM
Laurion Capital Management
New York
|
+$1.68M |
| 4 |
MIM
Monashee Investment Management
Boston,
Massachusetts
|
+$1.53M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$622K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ECM
ExodusPoint Capital Management
New York
|
-$515K |
| 2 |
CWM
CCG Wealth Management
San Diego,
California
|
-$269K |
| 3 |
SMG
Smart Money Group
Eastland,
Texas
|
-$250K |
| 4 |
AWA
Arete Wealth Advisors
Chicago,
Illinois
|
-$247K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$18K |
SMTI Hedge Fund Activity: Q1 2021 in Review
20 of the 5,696 institutional investors tracked by Wall St. Rank reported a position in Sanara MedTech (SMTI) for Q1 2021, worth a combined $17.2M — up 231% from $5.2M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new SMTI positions and 6 closed out — a net gain of 5 holders — while 5 added to existing stakes and 2 trimmed.
The largest buyer was Opaleye Management, opening a new position worth an estimated $7.8M. The largest seller was ExodusPoint Capital Management, exiting entirely with an estimated $515K sold.
- 20 institutional investors held Sanara MedTech (SMTI) as of Q1 2021, up from 15 in Q4 2020.
- Funds reported $17.2M of Sanara MedTech stock for Q1 2021, up 231% quarter-over-quarter.
- 11 funds opened new Sanara MedTech positions in Q1 2021 and 6 closed out, a net change of +5 holders.
- The largest Sanara MedTech buyer in Q1 2021 was Opaleye Management, an estimated $7.8M added.
- The largest Sanara MedTech seller in Q1 2021 was ExodusPoint Capital Management, an estimated $515K sold.
Based on aggregated 13F filings for Q1 2021.